TransMedics Group (NASDAQ:TMDX) Shares Gap Up After Better-Than-Expected Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $68.98, but opened at $79.12. TransMedics Group shares last traded at $83.8150, with a volume of 465,606 shares.

The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.30 by $0.21. The company had revenue of $203.01 million during the quarter, compared to analyst estimates of $178.06 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The business’s revenue was up 41.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.66 earnings per share.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue reached $203 million, up 41.1% year over year and above analyst expectations of about $178 million. EPS of $0.51 also beat the roughly $0.30 consensus. TransMedics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, signaling confidence in continued revenue growth. TransMedics raises 2026 revenue guidance
• Negative Sentiment: The company’s ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term milestones. EPS also declined from $0.66 in the year-ago quarter despite beating the latest consensus. TransMedics raises 2026 revenue guidance

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on TMDX shares. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. TD Cowen reiterated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Tuesday, September 8th. Piper Sandler reissued an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Barclays began coverage on shares of TransMedics Group in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target for the company. Finally, Canaccord Genuity Group set a $120.00 price target on shares of TransMedics Group in a research report on Friday. Five research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, TransMedics Group has a consensus rating of “Hold” and an average target price of $118.20.

Insider Transactions at TransMedics Group

In other news, Director David Weill bought 1,336 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the acquisition, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently made changes to their positions in the business. Braidwell LP grew its stake in shares of TransMedics Group by 85.1% in the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after purchasing an additional 280,324 shares during the last quarter. Deutsche Bank AG acquired a new stake in TransMedics Group during the second quarter valued at approximately $14,415,000. Bank of New York Mellon Corp acquired a new stake in TransMedics Group during the second quarter valued at approximately $12,869,000. Trek Financial LLC acquired a new stake in TransMedics Group during the third quarter valued at approximately $11,989,000. Finally, Legal & General Group Plc bought a new stake in TransMedics Group during the second quarter worth approximately $5,286,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Up 21.1%

The stock has a market capitalization of $2.89 billion, a P/E ratio of 21.47, a PEG ratio of 1.00 and a beta of 2.14. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The stock’s fifty day moving average is $79.68 and its two-hundred day moving average is $93.44.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.